Abstract:Cardiac arrhythmias cause significant morbidity and mortality and pose a major public health problem. They arise from disruptions in the normally orderly propagation of cardiac electrophysiological activation and recovery through successive cardiomyocytes in the heart. They reflect abnormalities in automaticity, initiation, conduction, or recovery in cardiomyocyte excitation. The latter properties are dependent on surface membrane electrophysiological mechanisms underlying the cardiac action potential. Their disruption results from spatial or temporal instabilities and heterogeneities in the generation and propagation of cellular excitation. These arise from abnormal function in their underlying surface membrane, ion channels, and transporters, as well as the interactions between them. The latter, in turn, form common regulatory targets for the hierarchical network of diverse signaling mechanisms reviewed here. In addition to direct molecular-level pharmacological or physiological actions on these surface membrane biomolecules, accessory, adhesion, signal transduction, and cytoskeletal anchoring proteins modify both their properties and localization. At the cellular level of excitation–contraction coupling processes, Ca 2+ homeostatic and phosphorylation processes affect channel activity and membrane excitability directly or through intermediate signaling. Systems -level autonomic cellular signaling exerts both acute channel and longer-term actions on channel expression. Further upstream intermediaries from metabolic changes modulate the channels both themselves and through modifying Ca 2+ homeostasis. Finally, longer-term organ -level inflammatory and structural changes, such as fibrotic and hypertrophic remodeling, similarly can influence all these physiological processes with potential pro-arrhythmic consequences. These normal physiological processes may target either individual or groups of ionic channel species and alter with particular pathological conditions. They are also potentially alterable by direct pharmacological action, or effects on longer-term targets modifying protein or cofactor structure, expression, or localization. Their participating specific biomolecules, often clarified in experimental genetically modified models, thus constitute potential therapeutic targets. The insights clarified by the physiological and pharmacological framework outlined here provide a basis for a recent modernized drug classification. Together, they offer a translational framework for current drug understanding. This would facilitate future mechanistically directed therapeutic advances, for which a number of examples are considered here. The latter are potentially useful for treating cardiac, in particular arrhythmic, disease.

Abstract 15963: Microrna Biophysically Modulates Cardiac Physiology Via Directly Binding to Ion Channel

Cardiac Hypertrophy and Dysfunction Induced by Overexpression of Mir-214 in Vivo

Regulation of human cardiac ion channel genes by microRNAs: theoretical perspective and pathophysiological implications

Small Molecules, Big Effects: the Role of Micrornas in Regulation of Cardiomyocyte Death

Silencing miR-370-3p rescues funny current and sinus node function in heart failure

MicroRNAs: novel regulators in cardiac development and disease

Dysregulated Expression of Micrornas and Mrnas in Myocardial Infarction.

Structural Mechanisms for the Activation of Human Cardiac KCNQ1 Channel by Electro-Mechanical Coupling Enhancers

MicroRNA Expression Profiles in a Human Induced Pluripotent Stem Cell‐derived Model of Diabetic Cardiomyopathy

Update on the Pathogenic Implications and Clinical Potential of microRNAs in Cardiac Disease

Cardiac arrhythmogenesis: roles of ion channels and their functional modification

miR-208a in Cardiac Hypertrophy and Remodeling

The role of lncRNAKCNQ1OT1/miR-301b/Tcf7 axis in cardiac hypertrophy

Novel roles of an intragenic G-quadruplex in controlling microRNA expression and cardiac function

MicroRNA-1 Accelerates the Shortening of Atrial Effective Refractory Period by Regulating KCNE1 and KCNB2 Expression: An Atrial Tachypacing Rabbit Model

Mir-1231 Exacerbates Arrhythmia by Targeting Calciumchannel Gene CACNA2D2 in Myocardial Infarction.

Mir-30d Regulates Cardiac Remodeling by Intracellular and Paracrine Signaling

Inhibiting microRNA-155 attenuates atrial fibrillation by targeting CACNA1C

miR-190a-5p Partially Represses the Abnormal Electrical Activity of SCN3B in Cardiac Arrhythmias by Downregulation of IL-2

Identification of Key Small Non‐Coding MicroRNAs Controlling Pacemaker Mechanisms in the Human Sinus Node

Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation